Annexon, Inc. $ANNX Stock Position Increased by Sei Investments Co.

Sei Investments Co. raised its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 248.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 203,236 shares of the company’s stock after purchasing an additional 144,977 shares during the period. Sei Investments Co. owned 0.12% of Annexon worth $1,126,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its stake in shares of Annexon by 13.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock valued at $100,000 after purchasing an additional 2,348 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Annexon by 65.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after buying an additional 2,785 shares during the period. Susquehanna Portfolio Strategies LLC boosted its position in shares of Annexon by 0.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after buying an additional 2,875 shares during the period. ProShare Advisors LLC grew its holdings in Annexon by 21.7% in the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock worth $124,000 after buying an additional 4,410 shares in the last quarter. Finally, Comerica Bank grew its holdings in Annexon by 26.4% in the 3rd quarter. Comerica Bank now owns 32,357 shares of the company’s stock worth $99,000 after buying an additional 6,750 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Needham & Company LLC raised their target price on Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research note on Friday, July 17th. Citizens Jmp initiated coverage on shares of Annexon in a research note on Tuesday, July 21st. They set a “market underperform” rating and a $3.00 price objective on the stock. Finally, Citigroup raised shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $15.33.

Insider Activity at Annexon

In other Annexon news, Director Muneer A. Satter bought 613,497 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the purchase, the director directly owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This trade represents a 6.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 10.31% of the stock is owned by insiders.

Annexon News Summary

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: Annexon reported encouraging early results from the FORWARD study of tanruprubart in Guillain-Barré syndrome, including rapid strength improvement and reduced disability. The company expects to submit a U.S. Biologics License Application in the fourth quarter of 2026, creating a significant near-term regulatory catalyst. Annexon second-quarter 2026 financial results and business updates
• Positive Sentiment: The company expanded the Phase 3 ARCHER II trial of vonaprument in geographic atrophy with a Month 24 dual-primary endpoint while retaining the Month 15 endpoint. Management said Month 15 results remain on track for the fourth quarter of 2026, potentially giving the program two independent opportunities to demonstrate vision-preserving efficacy. Annexon expands vonaprument Phase 3 program
• Positive Sentiment: A credit facility of up to $200 million, including $50 million drawn initially, is expected to extend Annexon’s cash runway into 2028. The company also expects proof-of-concept data for oral autoimmune-disease candidate ANX1502 in fall 2026.
• Neutral Sentiment: Unusually heavy options activity showed call purchases 244% above average, reflecting increased speculative interest but not necessarily a fundamental change in valuation or outlook.
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: Annexon reported a loss of $0.28 per share versus the $0.23 consensus estimate. Net loss increased to $55.3 million from $49.2 million year over year, while research and development expenses rose to $46.6 million.
• Negative Sentiment: The added Month 24 ARCHER II endpoint extends the final trial timeline into the third quarter of 2027, potentially delaying definitive results and commercialization. The credit facility improves liquidity but also increases reliance on external capital and future financing.

Annexon Stock Down 0.2%

NASDAQ:ANNX opened at $5.33 on Thursday. The business’s 50-day moving average price is $5.35 and its 200 day moving average price is $5.53. Annexon, Inc. has a 52-week low of $2.03 and a 52-week high of $7.18. The firm has a market cap of $873.27 million, a P/E ratio of -4.37 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). Sell-side analysts expect that Annexon, Inc. will post -0.92 EPS for the current year.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.